Reported 2 days ago
Novartis announced that its targeted radiotherapy, Pluvicto, has been shown to slow the progression of certain types of prostate cancer in earlier disease stages, as per a late-stage trial. This promising development indicates a potential to treat patients with metastatic prostate cancer still responsive to standard hormone therapy, addressing a significant unmet need. The company plans to seek regulatory approval for expanded use later this year.
Source: YAHOO